Impact of BCR-ABL mutations on patients with chronic myeloid leukemia.

@article{Hochhaus2011ImpactOB,
  title={Impact of BCR-ABL mutations on patients with chronic myeloid leukemia.},
  author={Andreas Hochhaus and Paul La Ros{\'e}e and Martin Christian M{\"u}ller and Thomas O G Ernst and Nicholas C P Cross},
  journal={Cell cycle},
  year={2011},
  volume={10 2},
  pages={250-60}
}
Therapies that target BCR-ABL in chronic myeloid leukemia, including imatinib, dasatinib and nilotinib, have dramatically improved patient outcome. BCR-ABL mutations, however, contribute to treatment resistance by disrupting drug contact sites or causing conformational changes thus making contact sites inaccessible. Clinical data indicate that developing BCR-ABL mutations during imatinib treatment is predictive for shorter progression-free survival, and that outcomes may depend on mutation type… CONTINUE READING
25 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

Similar Papers

Loading similar papers…